Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
- AWS helps Pfizer accelerate drug development and clinical manufacturing
- GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
- Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline
- Pfizer and BioNTech receive expanded U.S. FDA emergency use suthorization of COVID-19 vaccine booster to include individuals 18 and older
Research & Development
- Which COVID-19 vaccine works better?
- Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response
- ComCor study: New results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
- WHO update on Omicron
- Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
- International Cancer Genome Consortium empowers cancer researchers everywhere with new cloud computing platform
- Aspirin is linked with increased risk of heart failure
Conferences & Events
- Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai, ASC Therapeutics and Within3
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
Regulatory Affairs
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
- FDA takes additional actions on the use of a booster dose for COVID-19 vaccines
- FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments
- FDA approves innovative treatment for pediatric patients with congenital athymia